Materials

  • Innovative Breast Cancer Screening

    2D and 3D mammography may miss cancers in dense breasts 1, 2, potentially delaying diagnosis in these women. Both dense breast tissue and cancer appear white on a mammogram, creating a dangerous camouflage effect and a dilemma for radiologists whose goal is to find breast cancer as early as possible.

  • Improve Breast Cancer Dectection

    Mammography may miss over 1/3 of cancers in dense breasts.1 The InveniaTMABUS 2.0 (Automated Breast Ultrasound System) is a comfortable, nonionizing alternative to other supplemental screening options for women with dense breast tissue. When used in addition to mammography, Invenia ABUS 2.0 can improve breast cancer detection by 37.5 percent over mammography alone.2 Learn more about Invenia ABUS 2.0 by downloading the brochure.

  • Why is Invenia ABUS 2 screening needed

    Approximately 40% of women have dense breasts 4, one of the strongest common risk factors for developing breast cancer 5.  Having dense breasts increases a woman's chance of developing breast cancer by four to six times 6, and seventy-one percent of breast cancers are found in dense breasts. 7 Learn more about breast density by downloading a breast density informational sheet.

  • What are the steps in an Invenia ABUS 2.0 exam?

    The Invenia ABUS 2.0 acquisition process uses 3D ultrasound technology to comfortably and quickly image women with dense breast tissue. Each exam takes approximately 15 minutes.

    View the Invenia ABUS 2.0 acquisition process video.

evidence shows mammography ultrasounds aren't always reliable

Invenia ABUS 2.0 can improve early detection

      1. Mandelson et al. J Natl Cancer Inst 2000; 92:1081–1087.
      2. Tagliafico, Massimo Calabrese et al, Journal of Clinical Oncology 2016 34:16, 1882-1888.
      3. Brem et al, Radiology, March 2015.
      4. Pisano et al. NEJM 2005; 353: 1773.
      5. Engmann NJ, et al, JAMA Oncol. 2017;3(9):1228-1236
      6. Boyd NF et al. Mammographic Density and the Risk and Detection of Breast Cancer. NEJM 2007; 356: 227-36.
      7. Arora N, King TA, Jacks LM., Ann Surg Onc, 2010; 17:S211-18.

      JB02041US